PANDAR: a pivotal cancer-related long non-coding RNA in human cancers. Issue 11 (4th October 2017)

• Record Type: Journal Article
• Authors: Li, Jinglin; Li, Zhenglong; Zheng, Wangyang; Li, Xinheng; Wang, Zhidong; Cui, Yunfu; Jiang, Xingming
• Is Part Of: Molecular bioSystems. Volume 13:Issue 11(2017)
• Page Start: 2195
• Page End: 2201
• Publication Date: 2017-10-04
• Subjects: Molecular biology -- Periodicals; Biochemistry -- Periodicals; 571.7405
• DOI: 10.1039/c7mb00414a
• Languages: English
• ISSNs: 1742-206X

Abstract

Abstract : The dysregulation of PANDAR—a promising candidate among all tumor-associated lncRNAs—is involved in tumorigenesis and progression of diverse cancers. Abstract : Long non-coding RNAs (lncRNAs), non-protein-coding RNAs that are more than 200 nucleotides in length, have been demonstrated to play a vital role in the pathophysiology of human diseases, particularly in tumorigenesis and progression of cancers. Dysregulation of lncRNAs, which serve as either oncogenes or tumor suppressor genes, is involved in diverse cellular processes, such as proliferation, dedifferentiation, migration, invasion and anti-apoptosis. Promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR), which was recently found to manifest aberrant expression in various malignancies including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer and gastric cancer, is a novel cancer-related lncRNA. Deregulation of PANDAR contributes to tumorigenesis and progression of cancers, suggesting that PANDAR is likely to represent a viable biomarker and therapeutic target for human cancers. In this review, we summarize current evidence regarding the biological functions and mechanisms of PANDAR during tumor development.